Danaher Corp の最大収益セグメントは Other で、最新の利益発表における収益は -4,651,000,000 です。地域別に見ると、North America が Danaher Corp の主要市場であり、収益は 10,295,000,000 です。
Danaher Corpは収益を上げていますか?
はい、最新の財務諸表によると、Danaher Corpの純利益は$3,614です。
Danaher Corpに負債はありますか?
はい、Danaher Corpの負債は30,930です。
Danaher Corpの発行済株式数は何株ですか?
Danaher Corpの総発行済株式数は706.9株です。
360レポート
主要データ
前終値
$189.35
始値
$192.63
当日レンジ
$189.38 - $193.75
52週レンジ
$171 - $242.8
取引高
2.3M
平均取引高
3.8M
配当利回り
0.64%
1株当たり利益(TTM)
5.52
時価総額
$134.5B
DHRとは何ですか?
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.